Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.95B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 2.37M
Average 1.84M
DNLI Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Denali Therapeutics Inc.NASDAQ: DNLI
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation outflow grows to $22.92M
Q2 FY2026 stock-based compensation was $22.92M, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $69.95M. Over 3 fiscal years it compounded at -0.1% a year.
Context
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $22.92M or moves back toward the trailing-twelve-month quarterly average of $17.49M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 99.63M USD
- Year-over-year change
- -3.2%
- 4-year CAGR
- +4.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 99.63M | -3.2% |
| FY2024 | 2024-12-31 | 102.88M | -4.8% |
| FY2023 | 2023-12-31 | 108.1M | +8.3% |
| FY2022 | 2022-12-31 | 99.85M | +17.1% |
| FY2021 | 2021-12-31 | 85.25M | — |
Stock-Based Compensation vs competitors
How DNLI compares with its peers on the latest reported figures
- DNLI's LTM Jun 2026 stock-based compensation of $69.95M is the 5th largest of the 11 companies compared; the peer median is $29.58M.
- Its year-over-year change of +39.2% is the 3rd highest of 11, against a peer median of -4.4%.
- Stock-based compensation amounts to 1941.0% of revenue for DNLI, versus a peer median of 61.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $857.38M | +71257.3% | +9.4% | — | |
| LTM Sep 2026 | $235.1M | +4.2% | +8.0% | 6.4% | |
| LTM Sep 2026 | $132.29M | +4.4% | +10.1% | 13.8% | |
| LTM Jun 2026 | $85.94M | -13.0% | -16.6% | — | |
| LTM Jun 2026 | $69.95M | +39.2% | -0.1% | 1941.0% | |
| LTM Sep 2026 | $31.2M | +11.4% | +8.4% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
| LTM Sep 2026 | $26.2M | -19.6% | +5.9% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $21.78M | +70.4% | +213.9% | 108.9% |
| LTM Mar 2026 | $21.22M | -43.4% | -16.7% | 115.2% | |
| LTM Mar 2026 | $1.83M | -42.1% | -16.4% | — | |
| Peer median (excluding DNLI) | $29.58M | -4.4% | +8.2% | 61.3% | |
Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (290.58M) | (325.99M) | (145.22M) | (422.77M) | (512.54M) |
| Depreciation & Amortization | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 85.25M | 99.85M | 108.1M | 102.88M | 99.63M |
| Change in Working Capital | (20.41M) | (24.03M) | (289.93M) | 16.94M | 149K |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 3.71M | 2.27M | 2.43M | 1.44M | (7.52M) |
| Other Working Capital | (24.12M) | (26.3M) | (292.36M) | 15.5M | 7.67M |
| Other Non-Cash Items | 5.76M | (4.93M) | (47.67M) | (53.73M) | (14.65M) |
| Operating Cash Flow | (211.39M) | (244.72M) | (357.99M) | (347.69M) | (412.6M) |
| Capital Expenditures | (8.5M) | (17.83M) | (12.94M) | (15.91M) | (9.5M) |
| Acquisitions (Net) | 0 | 123.55M | 0 | 0 | 0 |
| Purchases of Investments | (1.42B) | (1.12B) | (1.81B) | (1.23B) | (441.26M) |
| Sales of Investments | 1.41B | 991.49M | 2.08B | 1.16B | 706.05M |
| Other Investing Activities | 0 | (123.55M) | 0 | 0 | 0 |
| Investing Cash Flow | (21.63M) | (141.39M) | 249.31M | (88.76M) | 255.28M |
| Debt Repayment | 0 | 0 | 0 | (32.34M) | (8.17M) |
| Common Stock Issued | 19.35M | 296.22M | 17.82M | 499.25M | 197.38M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 14.46M | 0 | 17.39M | 0 |
| Financing Cash Flow | 19.35M | 310.67M | 17.82M | 484.3M | 189.22M |
| Effect of Forex Changes | 0 | 0 | (75K) | 0 | 0 |
| Net Change in Cash | (213.67M) | (75.43M) | (90.94M) | 47.85M | 31.9M |
| Free Cash Flow | (219.89M) | (262.55M) | (370.93M) | (363.61M) | (422.1M) |
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.